Polus BioPharm Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was KRW 2.3 million compared to KRW 79.59 million a year ago. Net loss was KRW 595.96 million compared to KRW 4,343.11 million a year ago.

Basic loss per share from continuing operations was KRW 13 compared to KRW 108 a year ago. Basic loss per share was KRW 13 compared to KRW 108 a year ago.